These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 11882789)

  • 21. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents.
    Lee N; Hyeon T
    Chem Soc Rev; 2012 Apr; 41(7):2575-89. PubMed ID: 22138852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of certain variables on the tumor and tissue distribution of tracers V: false carrier effect, II, Fe.
    Hagan PL; Halpern SE; Stern PH; Gordon RM; Dabbs JE
    Invest Radiol; 1982; 17(1):53-60. PubMed ID: 7076435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hot-injection synthesis of iron/iron oxide core/shell nanoparticles for T2 contrast enhancement in magnetic resonance imaging.
    Herman DA; Ferguson P; Cheong S; Hermans IF; Ruck BJ; Allan KM; Prabakar S; Spencer JL; Lendrum CD; Tilley RD
    Chem Commun (Camb); 2011 Aug; 47(32):9221-3. PubMed ID: 21761066
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging.
    Lu J; Ma S; Sun J; Xia C; Liu C; Wang Z; Zhao X; Gao F; Gong Q; Song B; Shuai X; Ai H; Gu Z
    Biomaterials; 2009 May; 30(15):2919-28. PubMed ID: 19230966
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hybrid, metal oxide-peptide amphiphile micelles for molecular magnetic resonance imaging of atherosclerosis.
    Poon C; Gallo J; Joo J; Chang T; Bañobre-López M; Chung EJ
    J Nanobiotechnology; 2018 Nov; 16(1):92. PubMed ID: 30442135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of a chelating agent for accelerating excretion of radio-iron.
    FOREMAN H; HUFF RL; ODA JM; GARCIA J
    Proc Soc Exp Biol Med; 1952 Mar; 79(3):520-4. PubMed ID: 14920481
    [No Abstract]   [Full Text] [Related]  

  • 27. Ferrioxamine as a magnetic resonance contrast agent. Preclinical studies and phase I and II human clinical trials.
    Worah D; Berger AE; Burnett KR; Cockrill HH; Kanal E; Kendall C; Leese PT; Lyons KP; Ross E; Wolf GL
    Invest Radiol; 1988 Sep; 23 Suppl 1():S281-5. PubMed ID: 3058632
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Kinetics of radioactive osteotropic tracers in metabolic diseases of the skeleton].
    Caniggia A; Vattimo A
    Radiol Med; 1980 Oct; 66(10):723-6. PubMed ID: 7221035
    [No Abstract]   [Full Text] [Related]  

  • 29. Radioactivation of colloidal gamma ferric oxide.
    BLAU M; SINASON H; BAUDISCH O
    Science; 1946 Jun; 103(2687):744-8. PubMed ID: 20987697
    [No Abstract]   [Full Text] [Related]  

  • 30. [Molecular and parametric imaging with iron oxides].
    Matuszewski L; Tombach B; Heindel W; Bremer C
    Radiologe; 2007 Jan; 47(1):34-42. PubMed ID: 17203322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. How can superparamagnetic iron oxides be used to monitor disease and treatment?
    Unger EC
    Radiology; 2003 Dec; 229(3):615-6. PubMed ID: 14657295
    [No Abstract]   [Full Text] [Related]  

  • 32. Simple synthesis and functionalization of iron nanoparticles for magnetic resonance imaging.
    Cheong S; Ferguson P; Feindel KW; Hermans IF; Callaghan PT; Meyer C; Slocombe A; Su CH; Cheng FY; Yeh CS; Ingham B; Toney MF; Tilley RD
    Angew Chem Int Ed Engl; 2011 Apr; 50(18):4206-9. PubMed ID: 21472950
    [No Abstract]   [Full Text] [Related]  

  • 33. [Radioactive tracers for the study of myocardial perfusion in man. Characteristics and limitations].
    L'Abbate A
    G Ital Cardiol; 1988 May; 18(5):406-11. PubMed ID: 3056770
    [No Abstract]   [Full Text] [Related]  

  • 34. Iron Oxide Nanoparticles as Contrast Agents in Molecular Magnetic Resonance Imaging: Do They Open New Perspectives in Cardiovascular Imaging?
    Ploussi AG; Gazouli M; Stathis G; Kelekis NL; Efstathopoulos EP
    Cardiol Rev; 2015; 23(5):229-35. PubMed ID: 25688663
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo multimodal magnetic particle imaging (MPI) with tailored magneto/optical contrast agents.
    Arami H; Khandhar AP; Tomitaka A; Yu E; Goodwill PW; Conolly SM; Krishnan KM
    Biomaterials; 2015 Jun; 52():251-61. PubMed ID: 25818431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Iron oxide nanorods as high-performance magnetic resonance imaging contrast agents.
    Mohapatra J; Mitra A; Tyagi H; Bahadur D; Aslam M
    Nanoscale; 2015; 7(20):9174-84. PubMed ID: 25849780
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Superparamagnetic Iron Oxide Particles.
    Gore JC; Majumdar S
    Radiology; 1988 Dec; 169(3):657-8. PubMed ID: 3186988
    [No Abstract]   [Full Text] [Related]  

  • 38. Study of manganese bacteriopheophorbide as a potential contrast agent for magnetic resonance tomography.
    Meerovich IG; Brandis A; Meerovich GA; Stratonnikov AA; Bendel P; Oborotova NA; Shertz A; Baryshnikov AY
    Bull Exp Biol Med; 2007 Apr; 143(4):452-4. PubMed ID: 18214298
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cleaved iron oxide nanoparticles as T2 contrast agents for magnetic resonance imaging.
    Jeon SL; Chae MK; Jang EJ; Lee C
    Chemistry; 2013 Mar; 19(13):4217-22. PubMed ID: 23345158
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendronized iron oxide nanoparticles as contrast agents for MRI.
    Basly B; Felder-Flesch D; Perriat P; Billotey C; Taleb J; Pourroy G; Begin-Colin S
    Chem Commun (Camb); 2010 Feb; 46(6):985-7. PubMed ID: 20107672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.